Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...

86% ORR, 63% CR rate, 53% PFS at 12 months in patients who received vispa-cel with an optimized profile (N=35) Vispa-cel is generally well-tolerated, allowing for administration in the outpatient ...

The archived webcast will be available on the Caribou website for 30 days after the event ... Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing ...

Human egg cells are often prone to chromosomal errors. As women age, the error rate increases sharply - and can contribute to infertility, pregnancy ...

John L. Hennessy is President Emeritus of Stanford University as well as the James F. and Mary Lynn Gibbons Professor of ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

The global sales of DNA polymerase are estimated to be worth USD 397.7 million in 2025 and anticipated to reach a value of ...